Skip to content
Peptidepedia

AOD-9604 Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

AOD-9604 is sometimes used alongside other peptides in body composition protocols. These combinations are experimental, off-label, and lack clinical validation.

With GH secretagogues (CJC-1295/Ipamorelin): The rationale is complementary mechanisms. AOD-9604 targets lipolysis directly via the beta-3 AR pathway, while GH secretagogues stimulate endogenous growth hormone release for broader metabolic effects. Users typically administer AOD-9604 in the morning fasted and GH secretagogues before bed to align with natural GH pulsatility.

With BPC-157: This combination targets both body composition and tissue repair. BPC-157's anti-inflammatory and healing properties may complement AOD-9604's emerging cartilage-supportive effects, particularly for individuals with joint issues alongside body composition goals.

With other fat-loss peptides (tesamorelin, 5-amino-1MQ): Some protocols layer multiple lipolytic agents. Tesamorelin, an FDA-approved GHRH analog for HIV-associated lipodystrophy, is sometimes combined with AOD-9604 for additive fat-reduction effects, though no clinical data supports this combination.

All stacking protocols carry unknown interaction risks and should only be considered under medical supervision.

Frequently Asked Questions

Across six clinical trials involving 893 participants, AOD-9604 displayed a safety profile indistinguishable from placebo. The most commonly reported effects were mild injection-site reactions and occasional headaches. Unlike full HGH, it did not elevate IGF-1, impair glucose tolerance, or trigger antibody formation.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
  2. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.
  3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15.
  4. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77.
  5. Kok P, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. J Clin Endocrinol Metab. 2001;86(2):455-459.
  6. Obesity Pharmacotherapy: Current Perspectives and Future Directions. PMC. 2013.
  7. Kwon DR, et al. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-432.
  8. WADA Statement on Substance AOD-9604. World Anti-Doping Agency.
  9. FDA Pharmacy Compounding Advisory Committee Meeting, December 4, 2024.
  10. PubChem Compound Summary: AOD-9604. CID 71300630.
←Read the full AOD-9604 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”